Immune monitoring using mRNA-transfected dendritic cells

Methods in Molecular Biology

Volumn 1428, Issue , 2016, Pages 245-259

  Borch, Troels Holz ^a   Svane, Inge Marie ^a   Met, Özcan ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Cancer immunotherapy; Dendritic cell; Electroporation; Immune monitoring; mRNA transfection; Vaccination

Indexed keywords

DENDRITIC CELL VACCINE; MESSENGER RNA; TUMOR ANTIGEN; GAMMA INTERFERON; IFNG PROTEIN, HUMAN;

DENDRITIC CELL; GENETIC TRANSFECTION; HUMAN; IMMUNE RESPONSE; MONITORING; PERIPHERAL BLOOD MONONUCLEAR CELL; VACCINATION; ANTIGEN PRESENTATION; CELL CULTURE; CYTOLOGY; GENETICS; IMMUNOLOGICAL MONITORING; IMMUNOLOGY; METABOLISM; MONONUCLEAR CELL;

ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CELLS, CULTURED; DENDRITIC CELLS; HUMANS; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; MONITORING, IMMUNOLOGIC; RNA, MESSENGER; TRANSFECTION; VACCINATION;

EID: 84988860683     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-3625-0_16     Document Type: Chapter

References (14)

1. Palucka K, Banchereau J (2012) Cancer immunotherapy via dendritic cells. Nat Rev Cancer 12(4):265-277
2. Zaffaroni N, Costa A, Pennati M, De Marco C, Affini E, Madeo M et al (2007) Survivin is highly expressed and promotes cell survival in malignant peritoneal mesothelioma. Cell Oncol 29(6):453-466
3. Met O ¨, Balslev E, Flyger H, Svane IM (2011) High immunogenic potential of p53 mRNAtransfected dendritic cells in patients with primary breast cancer. Breast Cancer Res Treat 125(2):395-406
4. Vonderheide RH, Schultze JL, Anderson KS, Maecker B, Butler MO, Xia Z et al (2001) Equivalent induction of telomerase-specific cytotoxic T lymphocytes from tumor-bearing patients and healthy individuals advances in brief bearing patients and healthy individuals 1. Cancer Res 61:8366-8370
5. Andersen MH, Pedersen LØ, Capeller B, Class MHC, Epitopes IT, Bro E (2001) Spontaneous cytotoxic T-cell responses against survivinderived MHC Class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients advances in brief as well as ex vivo in cancer patients 1. Cancer Res 61:5964-5968
6. Mittal D, Gubin MM, Schreiber RD, Smyth MJ (2014) New insights into cancer immunoediting and its three component phaseselimination, equilibrium and escape. Curr Opin Immunol 27(1):16-25
7. Figdor CG, de Vries IJM, Lesterhuis WJ, Melief CJM (2004) Dendritic cell immunotherapy: mapping the way. Nat Med 10 (5):475-480
8. Met O ¨, Eriksen J, Svane IM (2008) Studies on mRNA electroporation of immature and mature dendritic cells: effects on their immunogenic potential. Mol Biotechnol 40 (2):151-160
9. Gilboa E (2007) Review series DC-based cancer vaccines. J Clin Invest 117 (5):1195-1203
10. Van Tendeloo VFI, Ponsaerts P, Lardon F, Nijs G, Lenjou M, Van Broeckhoven C et al (2001) Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: Superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood 98(1):49-56
11. Kantoff P, Higano C (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363(5):411-422
12. Met O¨, Svane IM (2013) Synthetic messenger RNA and cell metabolism modulation. Methods Mol Biol 969:275-292
13. Sæbøe-Larssen S, Fossberg E, Gaudernack G (2002) mRNA-based electrotransfection of human dendritic cells and induction of cytotoxic T lymphocyte responses against the telomerase catalytic subunit (hTERT). J Immunol Methods 259(1-2):191-203
14. Nielsen JS, Wick DA, Tran E, Nelson BH, Webb JR (2010) An in vitro-transcribedmRNA polyepitope construct encoding 32 distinct HLA class I-restricted epitopes from CMV, EBV, and Influenza for use as a functional control in human immune monitoring studies. J Immunol Methods 360(1-2):149-156